What does PHARMA LOVENJOEL do?

PHARMA LOVENJOEL is a pharmacy in Bierbeek. Public Limited, started on 8 January 2003, 1 establishment.

What is the address of PHARMA LOVENJOEL?

The registered office of PHARMA LOVENJOEL is located at Stationsstraat 21, 3360 Bierbeek.

Is PHARMA LOVENJOEL still active?

Yes. According to the CBE (30 October 2026) PHARMA LOVENJOEL is active, legal situation “Normale toestand”, started on 8 January 2003.

Is PHARMA LOVENJOEL registered on Peppol?

Yes, PHARMA LOVENJOEL is registered on the Peppol network with ID 0208:0479213355.

What is the enterprise number of PHARMA LOVENJOEL?

The enterprise number of PHARMA LOVENJOEL is BE0479213355.

When was PHARMA LOVENJOEL founded?

PHARMA LOVENJOEL was founded on 8 January 2003.

Who are the directors of PHARMA LOVENJOEL?

According to the 2025 annual accounts, the directors of PHARMA LOVENJOEL are: Kevin Dillaerts, Cuppie BV.

Is PHARMA LOVENJOEL a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 8 January 2003; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMA LOVENJOEL make in 2025?

PHARMA LOVENJOEL posted a profit after taxes of € 30,424 in financial year 2025.

What is the revenue of PHARMA LOVENJOEL?

As a small company, PHARMA LOVENJOEL is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 76,302.

PHARMA LOVENJOEL (Public Limited) - Bierbeek

Dossier PHARMA LOVENJOEL, printed on 30 October 2026 from databakkes.be/en/0479213355/pharma-lovenjoel. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 27 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PHARMA LOVENJOEL from Bierbeek, company number BE0479213355, closed financial year 2025 with a result of € 30,424 after tax. For that financial year PHARMA LOVENJOEL recorded a gross margin of € 76,302 and equity of € 83,201. Compared with financial year 2024, the result moved from € 29,884 to € 30,424. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on March 27, 2026.

What it is worth Growing

€ 83,201

▲ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 30,424

▲ 2% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 19,962

▼ 36% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 25,000 paid out

82 % of the profit went to the shareholders, mostly to CUPPIE (100 % of the shares). That is where the money ends up.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 150,750

▼ 30% vs 2024

€ 30,829 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 100,910

▲ 63% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 114,759 Gross margin 2022: € 114,759 First fiscal year in the series	€ 75,271 Gross margin 2023: € 75,271 ▼ 34% vs 2022 (€ 114,759) Unfavourable step	€ 69,298 Gross margin 2024: € 69,298 ▼ 8% vs 2023 (€ 75,271) Unfavourable step	€ 76,302 Gross margin 2025: € 76,302 ▲ 10% vs 2024 (€ 69,298) Favourable step	▲ 10%
Profit after taxes	€ 77,338 Profit after taxes 2022: € 77,338 First fiscal year in the series	€ 32,871 Profit after taxes 2023: € 32,871 ▼ 57% vs 2022 (€ 77,338) Unfavourable step	€ 29,884 Profit after taxes 2024: € 29,884 ▼ 9% vs 2023 (€ 32,871) Unfavourable step	€ 30,424 Profit after taxes 2025: € 30,424 ▲ 2% vs 2024 (€ 29,884) Favourable step	▲ 2%
Equity	€ 75,023 Equity 2022: € 75,023 First fiscal year in the series	€ 77,894 Equity 2023: € 77,894 ▲ 4% vs 2022 (€ 75,023) Favourable step	€ 77,777 Equity 2024: € 77,777 Unchanged (€ 77,894) Unfavourable step	€ 83,201 Equity 2025: € 83,201 ▲ 7% vs 2024 (€ 77,777) Favourable step	▲ 7%
Total debts	€ 512,317 Total debts 2022: € 512,317 First fiscal year in the series	€ 464,884 Total debts 2023: € 464,884 ▼ 9% vs 2022 (€ 512,317) Favourable step	€ 437,863 Total debts 2024: € 437,863 ▼ 6% vs 2023 (€ 464,884) Favourable step	€ 399,385 Total debts 2025: € 399,385 ▼ 9% vs 2024 (€ 437,863) Favourable step	▼ 9%
Cash	€ 43,506 Cash 2022: € 43,506 First fiscal year in the series	€ 50,406 Cash 2023: € 50,406 ▲ 16% vs 2022 (€ 43,506) Favourable step	€ 31,216 Cash 2024: € 31,216 ▼ 38% vs 2023 (€ 50,406) Unfavourable step	€ 19,962 Cash 2025: € 19,962 ▼ 36% vs 2024 (€ 31,216) Unfavourable step	▼ 36%
Land & buildings	€ 298,338 Land & buildings 2022: € 298,338 First fiscal year in the series	€ 286,534 Land & buildings 2023: € 286,534 ▼ 4% vs 2022 (€ 298,338) Unchanged	€ 274,730 Land & buildings 2024: € 274,730 ▼ 4% vs 2023 (€ 286,534) Unchanged	€ 262,926 Land & buildings 2025: € 262,926 ▼ 4% vs 2024 (€ 274,730) Unchanged	▼ 4%
Retained profit	€ 13,023 Retained profit 2022: € 13,023 First fiscal year in the series	€ 15,894 Retained profit 2023: € 15,894 ▲ 22% vs 2022 (€ 13,023) Favourable step	€ 15,777 Retained profit 2024: € 15,777 ▼ 1% vs 2023 (€ 15,894) Unfavourable step	€ 21,201 Retained profit 2025: € 21,201 ▲ 34% vs 2024 (€ 15,777) Favourable step	▲ 34%
Dividend	€ 75,000 Dividend 2022: € 75,000 First fiscal year in the series	€ 30,000 Dividend 2023: € 30,000 ▼ 60% vs 2022 (€ 75,000) Unchanged	€ 30,000 Dividend 2024: € 30,000 Unchanged (€ 30,000) Unchanged	€ 25,000 Dividend 2025: € 25,000 ▼ 17% vs 2024 (€ 30,000) Unchanged	▼ 17%
Bank debt	€ 307,433 Bank debt 2022: € 307,433 First fiscal year in the series	€ 257,593 Bank debt 2023: € 257,593 ▼ 16% vs 2022 (€ 307,433) Favourable step	€ 215,118 Bank debt 2024: € 215,118 ▼ 16% vs 2023 (€ 257,593) Favourable step	€ 150,750 Bank debt 2025: € 150,750 ▼ 30% vs 2024 (€ 215,118) Favourable step	▼ 30%
Balance sheet total	€ 587,340 Balance sheet total 2022: € 587,340 First fiscal year in the series	€ 542,778 Balance sheet total 2023: € 542,778 ▼ 8% vs 2022 (€ 587,340) Unchanged	€ 515,641 Balance sheet total 2024: € 515,641 ▼ 5% vs 2023 (€ 542,778) Unchanged	€ 482,587 Balance sheet total 2025: € 482,587 ▼ 6% vs 2024 (€ 515,641) Unchanged	▼ 6%

Key figures of PHARMA LOVENJOEL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to PHARMA LOVENJOEL?

What happened at PHARMA LOVENJOEL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2028 Kevin Dillaerts stepped down as director. NBB
2028 Cuppie BV stepped down as director. NBB
Mar 27, 2026 New annual accounts for financial year 2025: profit of € 30,424 (▲ 2% vs 2024). Source: NBB ↗
2022 Kevin Dillaerts became a director. NBB
2022 Cuppie BV became a director. NBB
Mar 4, 2003 New establishment in Bierbeek. KBO
Jan 8, 2003 Start of the company according to the CBE. KBO

In short

From € 77,338 profit in 2022 to € 30,424 profit in 2025.

Paid € 3,772 in corporate taxes since 2022.

Best year ever: 2022, with € 77,338 profit.

Paid out € 160,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

CUPPIE 100%

The stake of CUPPIE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMA LOVENJOEL

The shares are held by CUPPIE (100%).

Directors

According to the 2025 annual accounts

Kevin Dillaerts

Director

since 2022 · until 2028

Cuppie BV

Managing director · represented by Els Cuppens

since 2022 · until 2028

Shareholders

CUPPIE

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Stationsstraat 21

3360 Bierbeek

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0479.213.355

VAT number

BE 0479.213.355

Registered office

Stationsstraat 21, 3360 Bierbeek

Names & denominations

PHARMA LOVENJOEL

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

8 January 2003

Peppol

Active · Active since 1 Jan 2001

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA LOVENJOEL

Warning lights

Financials

What happened to PHARMA LOVENJOEL?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions